Trial of antibody for HIV Infection

Tanox, Inc. announced today that it has begun dosing patients in its Phase 2 clinical trial of TNX-355 for the treatment of the human immunodeficiency virus (HIV).

The Phase 2 study is a three-arm, double-blind, placebo-controlled study, which will enroll approximately 80 patients. All patients will be anti- retroviral therapy-experienced, and will also be placed on optimized background therapy during the study.

The objective of the study is to evaluate the safety and pharmacological activity of TNX-355 in combination with optimized background therapy as assessed by viral load reduction. TNX-355 will be administered every two weeks during the 48-week trial duration.

There is a planned interim evaluation at 24 weeks, which results are expected in 2005.

TNX-355 is a humanized, non-immunosuppressive anti-CD4 monoclonal antibody that works by blocking the ability of the virus to enter CD4 positive cells. T

he CD4 receptor on host cell surfaces is considered to be a gateway for HIV infection. This monoclonal antibody is one of a new class of drugs called viral entry inhibitors.

Results from earlier Phase 1 studies showed that TNX-355 was well tolerated and can cause transient but clinically meaningful reduction of viral load in patients infected with HIV, lasting approximately 2-4 weeks. TNX-355 received Fast Track status from the U.S. Food and Drug Administration (FDA) in 2003.

"We are very excited about the initiation of the Phase 2 trial of TNX-355 and its novel mechanism of action" said Nancy T. Chang, President and CEO of Tanox. "Moving this program forward will potentially help the HIV treatment- experienced patient population which currently has a limited number of treatment options."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Low neutralizing antibody titers against SARS-CoV-2 Mu in BNT162b2 vaccinated